CORT Quote, Financials, Valuation and Earnings

Bristol-Myers Squibb has a net margin of 16.9% compared to Corcept Therapeutics's net margin of 0.58%. Corcept Therapeutics's return on equity of 23.78% beat Bristol-Myers Squibb's return on equity of -46.27%.

Corcept Therapeutics has a consensus price target of $142.50, signalling upside risk potential of 55.01%. On the other hand Bristol-Myers Squibb has an analysts' consensus of $61.24 which suggests that it could grow by 2.84%. Given that Corcept Therapeutics has higher upside potential than Bristol-Myers Squibb, analysts believe Corcept Therapeutics is more attractive than Bristol-Myers Squibb.

Corcept Therapeutics has a beta of 0.145, which suggesting that the stock is 85.456% less volatile than S&P 500. In comparison Bristol-Myers Squibb has a beta of 0.408, suggesting its less volatile than the S&P 500 by 59.151%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol-Myers Squibb offers a yield of 4.06% to investors and pays a quarterly dividend of $0.62 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Bristol-Myers Squibb pays out -54.35% of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $181.9M, which are smaller than Bristol-Myers Squibb quarterly revenues of $12.3B. Corcept Therapeutics's net income of $30.7M is lower than Bristol-Myers Squibb's net income of $72M. Notably, Corcept Therapeutics's price-to-earnings ratio is 74.14x while Bristol-Myers Squibb's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 15.46x versus 2.50x for Bristol-Myers Squibb. Usually stocks with elevated PS ratios are considered overvalued.

Catalyst Pharmaceuticals has a net margin of 16.9% compared to Corcept Therapeutics's net margin of 39.44%. Corcept Therapeutics's return on equity of 23.78% beat Catalyst Pharmaceuticals's return on equity of 27.81%.

Corcept Therapeutics has a consensus price target of $142.50, signalling upside risk potential of 55.01%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $33.88 which suggests that it could grow by 41.62%. Given that Corcept Therapeutics has higher upside potential than Catalyst Pharmaceuticals, analysts believe Corcept Therapeutics is more attractive than Catalyst Pharmaceuticals.

Corcept Therapeutics has a beta of 0.145, which suggesting that the stock is 85.456% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.786, suggesting its less volatile than the S&P 500 by 21.371%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $181.9M, which are larger than Catalyst Pharmaceuticals quarterly revenues of $141.8M. Corcept Therapeutics's net income of $30.7M is lower than Catalyst Pharmaceuticals's net income of $55.9M. Notably, Corcept Therapeutics's price-to-earnings ratio is 74.14x while Catalyst Pharmaceuticals's PE ratio is 18.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 15.46x versus 6.08x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of 16.9% compared to Corcept Therapeutics's net margin of 24.89%. Corcept Therapeutics's return on equity of 23.78% beat Nektar Therapeutics's return on equity of -133.07%.

Corcept Therapeutics has a consensus price target of $142.50, signalling upside risk potential of 55.01%. On the other hand Nektar Therapeutics has an analysts' consensus of $4.75 which suggests that it could grow by 645.33%. Given that Nektar Therapeutics has higher upside potential than Corcept Therapeutics, analysts believe Nektar Therapeutics is more attractive than Corcept Therapeutics.

Corcept Therapeutics has a beta of 0.145, which suggesting that the stock is 85.456% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.381%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $181.9M, which are larger than Nektar Therapeutics quarterly revenues of $29.2M. Corcept Therapeutics's net income of $30.7M is higher than Nektar Therapeutics's net income of $7.3M. Notably, Corcept Therapeutics's price-to-earnings ratio is 74.14x while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 15.46x versus 1.33x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Supernus Pharmaceuticals has a net margin of 16.9% compared to Corcept Therapeutics's net margin of 8.8%. Corcept Therapeutics's return on equity of 23.78% beat Supernus Pharmaceuticals's return on equity of 7.61%.

Corcept Therapeutics has a consensus price target of $142.50, signalling upside risk potential of 55.01%. On the other hand Supernus Pharmaceuticals has an analysts' consensus of $38.80 which suggests that it could grow by 22.48%. Given that Corcept Therapeutics has higher upside potential than Supernus Pharmaceuticals, analysts believe Corcept Therapeutics is more attractive than Supernus Pharmaceuticals.

Corcept Therapeutics has a beta of 0.145, which suggesting that the stock is 85.456% less volatile than S&P 500. In comparison Supernus Pharmaceuticals has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.882%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Supernus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Supernus Pharmaceuticals pays out -- of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $181.9M, which are larger than Supernus Pharmaceuticals quarterly revenues of $174.2M. Corcept Therapeutics's net income of $30.7M is higher than Supernus Pharmaceuticals's net income of $15.3M. Notably, Corcept Therapeutics's price-to-earnings ratio is 74.14x while Supernus Pharmaceuticals's PE ratio is 23.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 15.46x versus 2.68x for Supernus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.